首页 > 最新文献

Transfusion Medicine and Hemotherapy最新文献

英文 中文
Erratum. 勘误。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-07-31 eCollection Date: 2024-10-01 DOI: 10.1159/000540195

[This corrects the article DOI: 10.1159/000533624.].

[此处更正了文章 DOI:10.1159/000533624]。
{"title":"Erratum.","authors":"","doi":"10.1159/000540195","DOIUrl":"https://doi.org/10.1159/000540195","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000533624.].</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"51 5","pages":"359"},"PeriodicalIF":1.9,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11494722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment. 遗传性端粒生物学疾病:病理生理学、临床表现、诊断和治疗。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-07-30 eCollection Date: 2024-10-01 DOI: 10.1159/000540109
Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, Tim H Brümmendorf

Background: Telomeres are the end-capping structures of all eukaryotic chromosomes thereby protecting the genome from damage and degradation. During the aging process, telomeres shorten continuously with each cell division until critically short telomeres prevent further proliferation whereby cells undergo terminal differentiation, senescence, or apoptosis. Premature aging due to critically short telomere length (TL) can also result from pathogenic germline variants in the telomerase complex or related genes that typically counteract replicative telomere shortening in germline and certain somatic cell populations, e.g., hematopoetic stem cells. Inherited diseases that result in altered telomere maintenance are summarized under the term telomere biology disorder (TBD).

Summary: Since TL both reflects but more importantly restricts the replicative capacity of various human tissues, a sufficient telomere reserve is particularly important in cells with high proliferative activity (e.g., hematopoiesis, immune cells, intestinal cells, liver, lung, and skin). Consequently, altered telomere maintenance as observed in TBDs typically results in premature replicative cellular exhaustion in the respective organ systems eventually leading to life-threatening complications such as bone marrow failure (BMF), pulmonary fibrosis, and liver cirrhosis.

Key messages: The recognition of a potential congenital origin in approximately 10% of adult patients with clinical BMF is of utmost importance for the proper diagnosis, appropriate patient and family counseling, to prevent the use of inefficient treatment and to avoid therapy-related toxicities including appropriate donor selection when patients have to undergo stem cell transplantation from related donors. This review summarizes the current state of knowledge about TBDs with particular focus on the clinical manifestation patterns in children (termed early onset TBD) compared to adults (late-onset TBD) including typical treatment- and disease course-related complications as well as their prognosis and adequate therapy. Thereby, it aims to raise awareness for a disease group that is currently still highly underdiagnosed particularly when it first manifests itself in adulthood.

背景:端粒是所有真核染色体的末端封闭结构,从而保护基因组免受损伤和降解。在衰老过程中,端粒会随着细胞的每次分裂而不断缩短,直到端粒极短,细胞无法进一步增殖,从而出现末端分化、衰老或凋亡。端粒酶复合体或相关基因中的致病性种系变异也会导致端粒长度(TL)极短而过早衰老,这些基因通常会抵消种系和某些体细胞群(如造血干细胞)中复制端粒的缩短。小结:由于端粒既反映了也更重要地限制了各种人体组织的复制能力,因此充足的端粒储备对于具有高增殖活性的细胞(如造血细胞、免疫细胞、肠道细胞、肝脏、肺和皮肤)尤为重要。因此,在 TBDs 中观察到的端粒维持的改变通常会导致相应器官系统的细胞复制能力过早衰竭,最终导致危及生命的并发症,如骨髓衰竭(BMF)、肺纤维化和肝硬化:在临床骨髓衰竭的成年患者中,约有10%的患者可能患有先天性骨髓衰竭,认识到这一疾病的潜在先天性来源,对于正确诊断、为患者和家属提供适当咨询、防止使用低效治疗方法、避免治疗相关毒性反应,包括在患者必须接受相关供体的干细胞移植时选择适当的供体至关重要。本综述总结了目前有关TBD的知识现状,尤其侧重于儿童(称为早发性TBD)与成人(晚发性TBD)相比的临床表现模式,包括典型的治疗和病程相关并发症及其预后和适当治疗。因此,本报告旨在提高人们对这一疾病群体的认识,因为目前这一疾病群体的诊断率仍然很低,尤其是在成年后首次发病时。
{"title":"Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment.","authors":"Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, Tim H Brümmendorf","doi":"10.1159/000540109","DOIUrl":"10.1159/000540109","url":null,"abstract":"<p><strong>Background: </strong>Telomeres are the end-capping structures of all eukaryotic chromosomes thereby protecting the genome from damage and degradation. During the aging process, telomeres shorten continuously with each cell division until critically short telomeres prevent further proliferation whereby cells undergo terminal differentiation, senescence, or apoptosis. Premature aging due to critically short telomere length (TL) can also result from pathogenic germline variants in the telomerase complex or related genes that typically counteract replicative telomere shortening in germline and certain somatic cell populations, e.g., hematopoetic stem cells. Inherited diseases that result in altered telomere maintenance are summarized under the term telomere biology disorder (TBD).</p><p><strong>Summary: </strong>Since TL both reflects but more importantly restricts the replicative capacity of various human tissues, a sufficient telomere reserve is particularly important in cells with high proliferative activity (e.g., hematopoiesis, immune cells, intestinal cells, liver, lung, and skin). Consequently, altered telomere maintenance as observed in TBDs typically results in premature replicative cellular exhaustion in the respective organ systems eventually leading to life-threatening complications such as bone marrow failure (BMF), pulmonary fibrosis, and liver cirrhosis.</p><p><strong>Key messages: </strong>The recognition of a potential congenital origin in approximately 10% of adult patients with clinical BMF is of utmost importance for the proper diagnosis, appropriate patient and family counseling, to prevent the use of inefficient treatment and to avoid therapy-related toxicities including appropriate donor selection when patients have to undergo stem cell transplantation from related donors. This review summarizes the current state of knowledge about TBDs with particular focus on the clinical manifestation patterns in children (termed early onset TBD) compared to adults (late-onset TBD) including typical treatment- and disease course-related complications as well as their prognosis and adequate therapy. Thereby, it aims to raise awareness for a disease group that is currently still highly underdiagnosed particularly when it first manifests itself in adulthood.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"51 5","pages":"292-309"},"PeriodicalIF":1.9,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulation of Blood Group Expression: Another Layer of Complexity to Consider. 血型表达的调控:需要考虑的另一层复杂性。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-07-02 eCollection Date: 2024-08-01 DOI: 10.1159/000539611
Christoph Gassner, Martin L Olsson
{"title":"Regulation of Blood Group Expression: Another Layer of Complexity to Consider.","authors":"Christoph Gassner, Martin L Olsson","doi":"10.1159/000539611","DOIUrl":"10.1159/000539611","url":null,"abstract":"","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"51 4","pages":"207-209"},"PeriodicalIF":1.9,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11318965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulation of the Lewis Blood Group Antigen Expression: A Literature Review Supplemented with Computational Analysis. 路易斯血型抗原表达的调控:文献综述与计算分析的补充。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-06-19 eCollection Date: 2024-08-01 DOI: 10.1159/000538863
Martin Wipplinger, Sylvia Mink, Maike Bublitz, Christoph Gassner

Background: The Lewis (Le) blood group system, unlike most other blood groups, is not defined by antigens produced internally to the erythrocytes and their precursors but rather by glycan antigens adsorbed on to the erythrocyte membrane from the plasma. These oligosaccharides are synthesized by the two fucosyltransferases FUT2 and FUT3 mainly in epithelial cells of the digestive tract and transferred to the plasma. At their place of synthesis, some Lewis blood group carbohydrate antigen variants also seem to be involved in various gastrointestinal malignancies. However, relatively little is known about the transcriptional regulation of FUT2 and FUT3.

Summary: To address this question, we screened existing literature and additionally used in silico prediction tools to identify novel candidate regulators for FUT2 and FUT3 and combine these findings with already known data on their regulation. With this approach, we were able to describe a variety of transcription factors, RNA binding proteins and microRNAs, which increase FUT2 and FUT3 transcription and translation upon interaction.

Key messages: Understanding the regulation of FUT2 and FUT3 is crucial to fully understand the blood group system Lewis (ISBT 007 LE) phenotypes, to shed light on the role of the different Lewis antigens in various pathologies, and to identify potential new diagnostic targets for these diseases.

背景:与其他大多数血型不同,路易斯(Le)血型系统不是由红细胞及其前体内部产生的抗原来定义的,而是由从血浆吸附到红细胞膜上的糖类抗原来定义的。这些寡糖主要由消化道上皮细胞中的两种岩藻糖转移酶 FUT2 和 FUT3 合成,然后转移到血浆中。在其合成地,一些路易斯血型碳水化合物抗原变体似乎也与各种胃肠道恶性肿瘤有关。摘要:为了解决这个问题,我们筛选了现有的文献,并额外使用了硅学预测工具来识别 FUT2 和 FUT3 的新型候选调控因子,并将这些发现与有关其调控的已知数据相结合。通过这种方法,我们能够描述各种转录因子、RNA 结合蛋白和 microRNA,它们在相互作用时会增加 FUT2 和 FUT3 的转录和翻译:关键信息:了解 FUT2 和 FUT3 的调控对于充分理解血型系统 Lewis(ISBT 007 LE)表型、阐明不同 Lewis 抗原在各种病症中的作用以及确定这些疾病的潜在新诊断靶点至关重要。
{"title":"Regulation of the Lewis Blood Group Antigen Expression: A Literature Review Supplemented with Computational Analysis.","authors":"Martin Wipplinger, Sylvia Mink, Maike Bublitz, Christoph Gassner","doi":"10.1159/000538863","DOIUrl":"10.1159/000538863","url":null,"abstract":"<p><strong>Background: </strong>The Lewis (Le) blood group system, unlike most other blood groups, is not defined by antigens produced internally to the erythrocytes and their precursors but rather by glycan antigens adsorbed on to the erythrocyte membrane from the plasma. These oligosaccharides are synthesized by the two fucosyltransferases <i>FUT2</i> and <i>FUT3</i> mainly in epithelial cells of the digestive tract and transferred to the plasma. At their place of synthesis, some Lewis blood group carbohydrate antigen variants also seem to be involved in various gastrointestinal malignancies. However, relatively little is known about the transcriptional regulation of <i>FUT2</i> and <i>FUT3</i>.</p><p><strong>Summary: </strong>To address this question, we screened existing literature and additionally used in silico prediction tools to identify novel candidate regulators for <i>FUT2</i> and <i>FUT3</i> and combine these findings with already known data on their regulation. With this approach, we were able to describe a variety of transcription factors, RNA binding proteins and microRNAs, which increase <i>FUT2</i> and <i>FUT3</i> transcription and translation upon interaction.</p><p><strong>Key messages: </strong>Understanding the regulation of <i>FUT2</i> and <i>FUT3</i> is crucial to fully understand the blood group system Lewis (ISBT 007 LE) phenotypes, to shed light on the role of the different Lewis antigens in various pathologies, and to identify potential new diagnostic targets for these diseases.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"51 4","pages":"225-236"},"PeriodicalIF":1.9,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11318966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HLA in Transplantation: Challenges and Perspectives. 移植中的 HLA:挑战与展望。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-06-03 eCollection Date: 2024-06-01 DOI: 10.1159/000538982
Nils Lachmann, Axel Pruß
{"title":"HLA in Transplantation: Challenges and Perspectives.","authors":"Nils Lachmann, Axel Pruß","doi":"10.1159/000538982","DOIUrl":"10.1159/000538982","url":null,"abstract":"","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"51 3","pages":"129-130"},"PeriodicalIF":2.2,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11166407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Persistent Antigen A after Minor ABO-Incompatible Hematopoietic Stem Cell Transplantation in Children: Two Case Reports. 儿童轻微abo -不相容造血干细胞移植后的持久性抗原A:两例报告。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-05-28 eCollection Date: 2024-12-01 DOI: 10.1159/000536176
Biljana Andrić, Zorica Radonjić, Olivera Šerbić, Dragana Vujić, Željko Zečević, Marija Simić, Borko Gobeljić, Snežana Jovanović-Srzentić, Ivana Radović

Introduction: ABO blood type changes after ABO-incompatible hematopoietic stem cell transplantation (HSCT). Most non-hematopoietic tissues retain the expression of the patient's own ABO antigens, which may adsorb from the plasma onto the donor's red blood cells (RBCs). Because of this phenomenon, a persistent patient's A and/or B antigen could be detected in the laboratory, despite 100% white cell donor chimerism. Adsorption of the patient's soluble ABO antigens on the newly formed RBCs complicates the interpretation of the patient's blood type and decision of transfusion therapy.

Case presentation: The first case report is a 6-year-old girl, A, D+, with T-cell acute lymphoblastic leukemia (ALL), transplanted with HLA-matched unrelated group O, D+ bone marrow. A second case report describes an 8-year-old girl, AB, D-, with ALL transplanted with an HLA-matched related group B, D+ bone marrow. The presence of persistent antigen A was registered in both patients more than 1 year after HSCT, despite complete donor chimerism.

Conclusion: The weak expression of ABO antigens on RBCs after HSCT should be examined in detail for proper planning of transfusion therapies.

ABO血型在ABO血型不相容的造血干细胞移植(HSCT)后发生改变。大多数非造血组织保留患者自身ABO抗原的表达,这些抗原可能从血浆中吸附到供者的红细胞(rbc)上。由于这种现象,尽管100%的白细胞供体嵌合,在实验室中仍可检测到患者的a和/或B抗原。患者的可溶性ABO抗原在新形成的红细胞上的吸附使患者血型的解释和输血治疗的决定复杂化。病例介绍:首例病例报告是一名6岁女孩,a, D+,患有t细胞急性淋巴细胞白血病(ALL),移植hla匹配无亲缘关系的O, D+组骨髓。第二个病例报告描述了一名8岁女孩,AB, D-, ALL移植与hla匹配的相关B, D+组骨髓。尽管供体嵌合完全,但在移植后1年多的时间里,两例患者均出现了持久性抗原A。结论:造血干细胞移植后红细胞上ABO抗原的弱表达应详细检查,以制定适当的输血治疗计划。
{"title":"Persistent Antigen A after Minor ABO-Incompatible Hematopoietic Stem Cell Transplantation in Children: Two Case Reports.","authors":"Biljana Andrić, Zorica Radonjić, Olivera Šerbić, Dragana Vujić, Željko Zečević, Marija Simić, Borko Gobeljić, Snežana Jovanović-Srzentić, Ivana Radović","doi":"10.1159/000536176","DOIUrl":"10.1159/000536176","url":null,"abstract":"<p><strong>Introduction: </strong>ABO blood type changes after ABO-incompatible hematopoietic stem cell transplantation (HSCT). Most non-hematopoietic tissues retain the expression of the patient's own ABO antigens, which may adsorb from the plasma onto the donor's red blood cells (RBCs). Because of this phenomenon, a persistent patient's A and/or B antigen could be detected in the laboratory, despite 100% white cell donor chimerism. Adsorption of the patient's soluble ABO antigens on the newly formed RBCs complicates the interpretation of the patient's blood type and decision of transfusion therapy.</p><p><strong>Case presentation: </strong>The first case report is a 6-year-old girl, A, D+, with T-cell acute lymphoblastic leukemia (ALL), transplanted with HLA-matched unrelated group O, D+ bone marrow. A second case report describes an 8-year-old girl, AB, D-, with ALL transplanted with an HLA-matched related group B, D+ bone marrow. The presence of persistent antigen A was registered in both patients more than 1 year after HSCT, despite complete donor chimerism.</p><p><strong>Conclusion: </strong>The weak expression of ABO antigens on RBCs after HSCT should be examined in detail for proper planning of transfusion therapies.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"51 6","pages":"439-443"},"PeriodicalIF":1.9,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11630906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erythrocyte Alloimmunization and Autoimmunization in the Pediatric Population: A Multicenter, Cross-Sectional Study in Central China. 儿童红细胞异体免疫和自身免疫:一项华中地区的多中心横断面研究。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-04-30 eCollection Date: 2024-12-01 DOI: 10.1159/000538448
Yongjun Wang, Yuanqing Yang, Zhengfeng Li, Wei Li, Hongbin Hu, Ding Zhao

Background: Erythrocyte alloantibodies and autoantibodies complicate transfusion. However, the prevalence of erythrocyte alloimmunization and autoimmunization has not been estimated in the Chinese pediatric population. Therefore, we investigated the prevalence of erythrocyte alloimmunization and autoimmunization in the Chinese pediatric population with the aim of developing a reasonable transfusion management policy in children from China.

Methods: This study included 30,603 pediatric inpatients who were admitted to three tertiary hospitals in central China from May 2020 to October 2022. Antibody screening was carried out with a three-cell panel by column agglutination technology, and samples with positive screening were analyzed for antibody specificity with a 16-cell identification panel. Clinical details of the patients were collected to identify associations with antibody formation.

Results: The alloimmunization rate was 0.55% (169/30,603), and the autoimmunization rate was 0.14% (43/30,603). Alloantibodies comprised 80.09% of the antibodies. The most frequent alloantibodies were anti-M (58.77%), anti-E (9.48%), and anti-P1 (4.27%). Autoantibodies comprised 19.91% of antibodies. Age (p = 0.000), sex (p = 0.016), geographical area (p = 0.000), ABO blood group (p = 0.008), and diagnosis (p = 0.000) were independent risk factors for antibody formation. The risk of antibody formation at the ages of 0-28 days and 1-3 months was zero (odds ratio = 0.000). The antibody distribution was significantly different by age (p = 0.000) and diagnosis (p = 0.000).

Conclusion: Repeat pre-transfusion testing for infants less than 4 months of age can be omitted for no risk of antibody formation. MNS system antibodies, especially anti-M, are prominent in younger children, and this decreases with age. Provision of extended phenotype-matched transfusion for Rh system antigens, especially antigen E, is necessary in children to control erythrocyte alloimmunization. The presence of antibodies with high evanescence rates in the pediatric population suggests the pressing need for nationwide shared transfusion records to avoid hemolytic transfusion reactions in children.

背景:红细胞同种异体抗体和自身抗体使输血复杂化。然而,红细胞同种异体免疫和自身免疫在中国儿童中的流行率尚未得到估计。因此,我们调查了中国儿科人群中红细胞同种异体免疫和自身免疫的患病率,旨在制定合理的中国儿童输血管理政策。方法:本研究纳入2020年5月至2022年10月在华中地区三所三级医院住院的30603例儿科住院患者。采用柱凝集技术进行抗体筛选,筛选阳性样品采用16细胞鉴定板进行抗体特异性分析。收集患者的临床细节以确定与抗体形成的关联。结果:异体免疫率为0.55%(169/30,603),自身免疫率为0.14%(43/30,603)。同种异体抗体占抗体的80.09%。最常见的同种异体抗体为抗m(58.77%)、抗e(9.48%)和抗p1(4.27%)。自身抗体占19.91%。年龄(p = 0.000)、性别(p = 0.016)、地理区域(p = 0.000)、ABO血型(p = 0.008)、诊断(p = 0.000)是抗体形成的独立危险因素。0 ~ 28日龄和1 ~ 3月龄抗体形成风险为0(优势比= 0.000)。抗体分布随年龄(p = 0.000)和诊断(p = 0.000)有显著差异。结论:4月龄以下婴儿输血前重复检测无抗体形成风险,可省略。MNS系统抗体,特别是抗m抗体,在幼儿中很突出,随着年龄的增长而减少。提供广泛的表型匹配输血的Rh系统抗原,特别是抗原E,是必要的,以控制儿童红细胞同种免疫。儿童人群中存在高消失率的抗体,这表明迫切需要在全国范围内共享输血记录,以避免儿童溶血性输血反应。
{"title":"Erythrocyte Alloimmunization and Autoimmunization in the Pediatric Population: A Multicenter, Cross-Sectional Study in Central China.","authors":"Yongjun Wang, Yuanqing Yang, Zhengfeng Li, Wei Li, Hongbin Hu, Ding Zhao","doi":"10.1159/000538448","DOIUrl":"10.1159/000538448","url":null,"abstract":"<p><strong>Background: </strong>Erythrocyte alloantibodies and autoantibodies complicate transfusion. However, the prevalence of erythrocyte alloimmunization and autoimmunization has not been estimated in the Chinese pediatric population. Therefore, we investigated the prevalence of erythrocyte alloimmunization and autoimmunization in the Chinese pediatric population with the aim of developing a reasonable transfusion management policy in children from China.</p><p><strong>Methods: </strong>This study included 30,603 pediatric inpatients who were admitted to three tertiary hospitals in central China from May 2020 to October 2022. Antibody screening was carried out with a three-cell panel by column agglutination technology, and samples with positive screening were analyzed for antibody specificity with a 16-cell identification panel. Clinical details of the patients were collected to identify associations with antibody formation.</p><p><strong>Results: </strong>The alloimmunization rate was 0.55% (169/30,603), and the autoimmunization rate was 0.14% (43/30,603). Alloantibodies comprised 80.09% of the antibodies. The most frequent alloantibodies were anti-M (58.77%), anti-E (9.48%), and anti-P1 (4.27%). Autoantibodies comprised 19.91% of antibodies. Age (<i>p</i> = 0.000), sex (<i>p</i> = 0.016), geographical area (<i>p</i> = 0.000), ABO blood group (<i>p</i> = 0.008), and diagnosis (<i>p</i> = 0.000) were independent risk factors for antibody formation. The risk of antibody formation at the ages of 0-28 days and 1-3 months was zero (odds ratio = 0.000). The antibody distribution was significantly different by age (<i>p</i> = 0.000) and diagnosis (<i>p</i> = 0.000).</p><p><strong>Conclusion: </strong>Repeat pre-transfusion testing for infants less than 4 months of age can be omitted for no risk of antibody formation. MNS system antibodies, especially anti-M, are prominent in younger children, and this decreases with age. Provision of extended phenotype-matched transfusion for Rh system antigens, especially antigen E, is necessary in children to control erythrocyte alloimmunization. The presence of antibodies with high evanescence rates in the pediatric population suggests the pressing need for nationwide shared transfusion records to avoid hemolytic transfusion reactions in children.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"51 6","pages":"402-413"},"PeriodicalIF":1.9,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11630902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cell Salvage Using the Autotransfusion Device CATSmart®: A Randomized Controlled Bicentric Trial Evaluating the Quality of Two New Flex Wash Programs. 细胞回收使用自体输血装置CATSmart®:一项随机对照双中心试验评估两个新的柔性洗涤程序的质量。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-04-02 eCollection Date: 2024-12-01 DOI: 10.1159/000536322
Sven Arends, Michael Thomas, Michael Nosch, Thomas Droll, Denise Zwanziger, Thorsten Brenner, Ali Haddad

Background: The use of cell salvage and autologous blood transfusion is an important and widespread method of blood conservation during surgeries with expected high blood loss. The continuous autotransfusion device CATSmart® (Fresenius Kabi, Germany) contains two new washing programs on the device called Flex wash 3 and Flex wash 5. To the best of our knowledge, there are no published clinical data regarding the performance of the two new washing programs.

Methods: In total, 69 patients undergoing cardiac or orthopedic surgery were included in this randomized, controlled, bicentric trial to validate the red cell separation process and washout quality of Flex wash 3 compared to Flex wash 5. After washing, the primary quality target was to determine hematocrit value, recovery rate, albumin, and total protein elimination rate in the packed red cells (PRCs). The secondary objective was to assess the elimination of heparin by measuring the factor anti-Xa activity by a 1- and 2-stage assay in PRC after washing.

Results: In the whole cohort of patients, hematocrit was 16.00% [9.15%; 21.30%] (median [Q1; Q3]) in the wound blood and 69.90% [51.10%; 80.90%] in the PRC resulting in a recovery rate of 63.92% [47.06%; 88.13%]. The albumin elimination rate was 98.77% [97.94%; 99.27%], and the total protein elimination rate was 98.85% [97.76%; 99.42%]. The heparin elimination rate was 99.95% [99.90%; 99.97%] in the 1-stage assay and 99.70% [99.41%; 99.87%] in the 2-stage assay. There was no difference between Flex wash 3 and Flex wash 5 washing procedure regarding the recovery rate 63.75% [46.64%; 78.65%] versus 67.89% [47.20%; 92.69%] (p = 0.85), albumin elimination rate 98.74% [97.67%; 99.27%] versus 98.78% [98.10%; 99.28%] (p = 0.97), protein elimination rate 98.79% [97.94%; 99.47%] versus 98.92% [97.58%; 99.42%] (p = 0.88), and anti-Xa elimination rate in the 1-stage assay 99.94% [99.79%; 99.97%] versus 99.95% [99.92%; 99.97%] (p = 0.24) and in 2-stage assay 99.66% [99.20%; 99.86%] versus 99.77% [99.47%; 99.90%] (p = 0.23).

Conclusions: The two new washing procedures, Flex wash 3 and Flex wash 5, enable sufficient and comparable red cell separation and washout quality of albumin, total protein, as well as heparin.

背景:在预期失血较多的手术中,使用细胞保留和自体输血是一种重要而广泛的血液保存方法。连续自体输血设备CATSmart®(Fresenius Kabi,德国)在设备上包含两个新的洗涤程序,称为Flex wash 3和Flex wash 5。据我们所知,目前还没有关于这两种新洗涤程序性能的公开临床数据。方法:共有69例接受心脏或骨科手术的患者被纳入这项随机、对照、双中心试验,以验证Flex wash 3与Flex wash 5相比的红细胞分离过程和洗脱质量。洗涤后,主要质量指标是测定红细胞压积值、回收率、白蛋白和填充红细胞(PRCs)中的总蛋白消除率。次要目的是通过在PRC洗涤后通过1和2阶段测定测量抗xa因子活性来评估肝素的消除。结果:在整个队列患者中,血细胞比容为16.00% [9.15%;21.30%](中位数[Q1;Q3]), 69.90% [51.10%];80.90%],回收率为63.92% [47.06%;88.13%)。白蛋白清除率为98.77% [97.94%;总蛋白清除率为98.85% [97.76%];99.42%)。肝素清除率为99.95% [99.90%;99.97%]和99.70% [99.41%;99.87%]。Flex wash 3和Flex wash 5两种清洗方式的回收率分别为63.75%和46.64%;78.65% vs 67.89% [47.20%;92.69%] (p = 0.85),白蛋白清除率98.74% [97.67%];99.27% vs . 98.78% [98.10%;99.28%] (p = 0.97),蛋白质清除率98.79% [97.94%];99.47% vs . 98.92% [97.58%;99.42%] (p = 0.88),一期法抗xa清除率为99.94% [99.79%;99.97%对99.95% [99.92%;99.97%] (p = 0.24),两阶段试验99.66% [99.20%;99.86% vs . 99.77% [99.47%;99.90%] (p = 0.23)。结论:Flex wash 3和Flex wash 5这两种新的洗涤方法能够充分地分离红细胞,并能保证白蛋白、总蛋白和肝素的洗脱质量。
{"title":"Cell Salvage Using the Autotransfusion Device CATSmart<sup>®</sup>: A Randomized Controlled Bicentric Trial Evaluating the Quality of Two New Flex Wash Programs.","authors":"Sven Arends, Michael Thomas, Michael Nosch, Thomas Droll, Denise Zwanziger, Thorsten Brenner, Ali Haddad","doi":"10.1159/000536322","DOIUrl":"10.1159/000536322","url":null,"abstract":"<p><strong>Background: </strong>The use of cell salvage and autologous blood transfusion is an important and widespread method of blood conservation during surgeries with expected high blood loss. The continuous autotransfusion device CATSmart<sup>®</sup> (Fresenius Kabi, Germany) contains two new washing programs on the device called Flex wash 3 and Flex wash 5. To the best of our knowledge, there are no published clinical data regarding the performance of the two new washing programs.</p><p><strong>Methods: </strong>In total, 69 patients undergoing cardiac or orthopedic surgery were included in this randomized, controlled, bicentric trial to validate the red cell separation process and washout quality of Flex wash 3 compared to Flex wash 5. After washing, the primary quality target was to determine hematocrit value, recovery rate, albumin, and total protein elimination rate in the packed red cells (PRCs). The secondary objective was to assess the elimination of heparin by measuring the factor anti-Xa activity by a 1- and 2-stage assay in PRC after washing.</p><p><strong>Results: </strong>In the whole cohort of patients, hematocrit was 16.00% [9.15%; 21.30%] (median [Q1; Q3]) in the wound blood and 69.90% [51.10%; 80.90%] in the PRC resulting in a recovery rate of 63.92% [47.06%; 88.13%]. The albumin elimination rate was 98.77% [97.94%; 99.27%], and the total protein elimination rate was 98.85% [97.76%; 99.42%]. The heparin elimination rate was 99.95% [99.90%; 99.97%] in the 1-stage assay and 99.70% [99.41%; 99.87%] in the 2-stage assay. There was no difference between Flex wash 3 and Flex wash 5 washing procedure regarding the recovery rate 63.75% [46.64%; 78.65%] versus 67.89% [47.20%; 92.69%] (<i>p</i> = 0.85), albumin elimination rate 98.74% [97.67%; 99.27%] versus 98.78% [98.10%; 99.28%] (<i>p</i> = 0.97), protein elimination rate 98.79% [97.94%; 99.47%] versus 98.92% [97.58%; 99.42%] (<i>p</i> = 0.88), and anti-Xa elimination rate in the 1-stage assay 99.94% [99.79%; 99.97%] versus 99.95% [99.92%; 99.97%] (<i>p</i> = 0.24) and in 2-stage assay 99.66% [99.20%; 99.86%] versus 99.77% [99.47%; 99.90%] (<i>p</i> = 0.23).</p><p><strong>Conclusions: </strong>The two new washing procedures, Flex wash 3 and Flex wash 5, enable sufficient and comparable red cell separation and washout quality of albumin, total protein, as well as heparin.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"51 6","pages":"367-372"},"PeriodicalIF":1.9,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11631003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum. 勘误。
IF 1.9 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-03-22 eCollection Date: 2024-06-01 DOI: 10.1159/000534302

[This corrects the article DOI: 10.1159/000533624.].

[此处更正了文章 DOI:10.1159/000533624]。
{"title":"Erratum.","authors":"","doi":"10.1159/000534302","DOIUrl":"https://doi.org/10.1159/000534302","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000533624.].</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"51 3","pages":"198"},"PeriodicalIF":1.9,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prolonged Thrombocytopenia and Severe Transfusion Reaction after ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation in a Patient with Chronic Myelomonocytic Leukemia 一名慢性粒单核细胞白血病患者接受 ABO 不相容异基因造血干细胞移植后出现长时间血小板减少和严重输血反应
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-01-09 DOI: 10.1159/000534272
Lina S. Silva-Bermúdez, D. Heidenreich, Stefan A. Klein, Patrick Wuchter, Harald Klüter, Sabine Kayser
Introduction: Major ABO-incompatible allogeneic hematopoietic stem cell transplantation (allo-HCT) is a common practice and represents a challenging transfusion scenario. Prolonged thrombocytopenia with increased platelet transfusion needs is one of its reported adverse effects, and this has been linked to the persistence of recipient anti-donor isoagglutinins. Case Presentation: A 55-year-old male patient, O Rh(D)-positive, with chronic myelomonocytic leukemia underwent major incompatible allo-HCT from a A Rh(D)-negative donor. He presented with prolonged thrombocytopenia and multiple transfusion reactions after A Rh(D)-negative platelet transfusions. Considering the outcomes of numerous examinations, we tested the anti-A1 titers, finding a significant persistence of anti-donor isoagglutinins. We limited platelet transfusions to blood group O Rh(D)-negative donors, which significantly decreased the requirement for platelet transfusions. In addition, the transfusion reactions ceased. Conclusion: In case of transfusion reactions against platelet products in major ABO-incompatible allo-HCT patients, isoagglutinin monitoring should be considered and a change in the platelet transfusion protocol may be beneficial in patients presenting high isotiters against recipient’s blood type.
导言:ABO不相容异基因造血干细胞移植(allo-HCT)是一种常见的治疗方法,也是一种具有挑战性的输血方案。据报道,血小板减少时间延长、血小板输注需求增加是其不良反应之一,这与受体抗供体异凝集素的持续存在有关。病例介绍:一名 55 岁的男性患者,O 型 Rh(D)阳性,患有慢性粒单核细胞白血病,接受了来自 A 型 Rh(D)阴性供体的主要不相容异体造血干细胞移植。在输注 A 型 Rh(D) 阴性血小板后,他出现了长时间血小板减少和多次输血反应。考虑到多次检查的结果,我们检测了抗 A1 滴度,发现抗供体异凝集素显著持续存在。我们将血小板输注限制在血型为 O 型 Rh(D)阴性的献血者身上,这大大降低了血小板输注的需求量。此外,输血反应也停止了。结论如果主要 ABO 血型不相容的异体肝移植患者出现血小板产品输血反应,应考虑进行等凝集素监测,改变血小板输注方案可能对出现受体血型高等凝集素的患者有益。
{"title":"Prolonged Thrombocytopenia and Severe Transfusion Reaction after ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation in a Patient with Chronic Myelomonocytic Leukemia","authors":"Lina S. Silva-Bermúdez, D. Heidenreich, Stefan A. Klein, Patrick Wuchter, Harald Klüter, Sabine Kayser","doi":"10.1159/000534272","DOIUrl":"https://doi.org/10.1159/000534272","url":null,"abstract":"Introduction: Major ABO-incompatible allogeneic hematopoietic stem cell transplantation (allo-HCT) is a common practice and represents a challenging transfusion scenario. Prolonged thrombocytopenia with increased platelet transfusion needs is one of its reported adverse effects, and this has been linked to the persistence of recipient anti-donor isoagglutinins. Case Presentation: A 55-year-old male patient, O Rh(D)-positive, with chronic myelomonocytic leukemia underwent major incompatible allo-HCT from a A Rh(D)-negative donor. He presented with prolonged thrombocytopenia and multiple transfusion reactions after A Rh(D)-negative platelet transfusions. Considering the outcomes of numerous examinations, we tested the anti-A1 titers, finding a significant persistence of anti-donor isoagglutinins. We limited platelet transfusions to blood group O Rh(D)-negative donors, which significantly decreased the requirement for platelet transfusions. In addition, the transfusion reactions ceased. Conclusion: In case of transfusion reactions against platelet products in major ABO-incompatible allo-HCT patients, isoagglutinin monitoring should be considered and a change in the platelet transfusion protocol may be beneficial in patients presenting high isotiters against recipient’s blood type.","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"35 33","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139442847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Transfusion Medicine and Hemotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1